vTv Therapeutics Inc.

Listed Company

VTVTCIK 0001641489NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

$-26.97M

Total Assets

$89.90M

Equity

$64.44M

Shares Out

Op. Cash Flow

$-25.25M

Business

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases. Its main product candidate is cadisegliatin (TTP399), a liver-selective glucokinase activator being developed as an adjunct to insulin for type 1 diabetes, alongside other programs including an oral GLP-1 receptor agonist (TTP273), Nrf2/Bach1 modulators (HPP3033), and a PDE4 inhibitor (HPP737). The company conducts clinical development internally and through collaborations and licensing arrangements, with partnered programs and third-party manufacturing. vTv pursues regulatory and clinical activities in the United States and internationally, including trials in the Middle East and other partner territories.

Summary from filing dated 2025-03-20

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	0	1	0	2	4
Research and development	18	12	14	12	13
General and administrative	15	14	12	12	12
Total operating expenses	33	25	26	25	26
Operating loss	−33	−24	−26	−23	−22
Interest income	2	2	472,000	352,000	1,000
Interest expense	−6,000	0	−13,000	—	—
Loss before income taxes and noncontrolling interest	−31	−23	−26	−25	−18
Income tax provision	0	100,000	0	200,000	100,000
Net loss before noncontrolling interest	−31	−23	−26	−25	−18
Net loss attributable to noncontrolling interest	−4	−4	−6	−6	−5
Net loss attributable to vTv Therapeutics Inc.	−27	−18	−20	−19	−13
Net loss attributable to vTv Therapeutics Inc. common shareholders	−27	−18	−20	−19	−13

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	89	37	9	12	13
Prepaid expenses	743,000	1	—	—	—
Other current assets	218,000	175,000	—	—	—
Total current assets	90	38	11	27	16
Other assets	6,000	153,000	—	—	—
Total assets	90	38	11	33	25
Accounts payable and accrued expenses	7	5	10	7	8
Current portion of operating lease liabilities	0	169,000	169,000	154,000	184,000
Total current liabilities	7	5	11	8	8
Contract liabilities, net of current portion	19	19	19	19	0
Total liabilities	25	24	30	27	10
Commitments and contingencies	—	—	—	—	—
Additional paid-in capital	391	312	256	255	238
Accumulated deficit	−327	−300	−281	−266	−249
Total stockholders equity attributable to vTv Therapeutics Inc.	64	12	−25	−11	−10
Noncontrolling interest	0	2	0	—	—
Total stockholders equity	64	14	−25	−11	−10
Total liabilities, redeemable noncontrolling interest and stockholders equity	90	38	11	33	25

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation expense	16,000	89,000	90,000	100,000	100,000
Loss on disposal of property and equipment	6,000	0	0	—	—
Loss from G42 Promissory Note early redemption	0	0	313,000	0	0
Non-cash interest income	0	0	−100,000	−352,000	0
Share-based compensation expense	4	3	2	1	2
Realized gain on sale of investment in Reneo Pharmaceuticals, Inc.	0	0	−3	0	0
Impairment of investments in Anteris Bio, Inc.	0	0	4	0	0
Prepaid expenses	449,000	−216,000	2	−403,000	−839,000
Other current assets	−43,000	60,000	−37,000	—	—
Other assets	125,000	119,000	105,000	—	—
Accounts payable and accrued expenses	2	−5	3	−856,000	2
Contract liabilities	0	−17,000	0	7	−1
Other liabilities	−169,000	−169,000	−154,000	0	−50,000
Net cash used in operating activities	−25	−25	−19	−16	−19
Proceed from sale of investments in Reneo Pharmaceuticals, Inc.	0	0	4	0	0
Net cash provided by (used in) investing activities	0	0	4	−21,000	0
Proceeds from sale of Class A common stock, pre-funded and common warrants, net of offering costs	77	0	0	—	—
Proceeds from sale of Class A common stock and pre-funded warrants, net of offering costs	0	50	0	0	0
Proceeds from issuance of Class A common stock, net of offering costs	0	2	0	0	27
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs	0	0	12	5	0
Proceeds from the exercise of stock options	16,000	0	0	0	47,000
Taxes paid related to net share settlement of equity awards	−51,000	0	0	—	—
Proceeds from debt issuance	392,000	0	566,000	776,000	887,000
Repayment of notes payable	−392,000	−191,000	−599,000	−808,000	−715,000
Net cash provided by financing activities	77	53	12	15	27
Net increase (decrease) in cash, cash equivalents	52	27	−3	−1	8
Cash paid for interest	6,000	2,000	14,000	15,000	11,000
Cash paid for income taxes	0	100,000	0	200,000	115,000
Reclassification of noncontrolling interest to additional paid-in capital	2	5	0	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro